Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 2 Tage 19 Stunden
@MorphoSys
Proud to announce the start of the pivotal Phase 3 frontMIND #clinicaltrial evaluating our CD19-directed antibody a… https://t.co/ilQQtvIeDK
vor 1 Woche 1 Tag
@MorphoSys
At MorphoSys, we appreciate the hard work of our nurse partners and we are excited to celebrate #NationalNursesWeek… https://t.co/NLmtD8GAHU
vor 1 Woche 1 Tag
@MorphoSys
Today we reported financial results for the first quarter 2021. Read the full results and business update here:… https://t.co/QzGPkH9TYM
vor 3 Wochen 3 Tage
@MorphoSys
Today, we announced in partnership with @Incyte the initiation of the Phase 3 inMIND #clinicaltrial for our CD19 an… https://t.co/iyKI4zJF1x
vor 3 Wochen 3 Tage
@MorphoSys
Congratulations to our CEO Jean-Paul Kress for being honored by @medicine_maker in their 2021 Power List… https://t.co/gv7JpPjP2i
vor 1 Monat 3 Wochen
@MorphoSys
Since the founding of MorphoSys, it’s been our goal to make a sustainable, positive impact on the environment, soci… https://t.co/6QzLK9OduI
vor 1 Monat 3 Wochen
@MorphoSys
Annual Report: Take a closer look at how we – despite all the challenges of 2020 – transformed as a company and bro… https://t.co/w9C56tNXlj
vor 1 Monat 4 Wochen
@MorphoSys
Today we reported our full year and fourth quarter 2020 results and business updates. Read the full results here:… https://t.co/pdIB2336Qz
vor 2 Monate 6 Stunden
@MorphoSys
Our Business Development Team will be participating at #BioEuropeSpring, March 22-25, 2021. We look forward to conn… https://t.co/2Laj545sPr
vor 2 Monate 1 Woche
@MorphoSys
We are pleased that our licensing partner @GSK is continuing to explore an antibody generated by MorphoSys as a pot… https://t.co/e96LSsV4st
Investorenkontakt
Dr. Julia Neugebauer
Senior Director Investor Relations
Telefon +49 89 89927 179
Myles Clouston
Senior Director, Head of US Investor Relations
Telefon +1 857 772 0240
Medienkontakt
Thomas Biegi
Vice President, Head of Corporate Communications
Telefon +49 89 89927 26079
Sophie Petersen
Senior Specialist Corporate Communications
Telefon +49 89 89927 26033
Fax: +49 89 89927 526033